Table of contents
Ventricular arrhythmias
Guidelines
Key sources
Diagnostic investigations
More topics in this section
ECG
Holter monitoring
Implantable cardiac monitors
Echocardiography
Cardiac MRI
Natriuretic peptides
Genetic testing
Psychosocial assessment
Evaluation for reversible causes
Evaluation of premature ventricular complexes
Evaluation of PVC-induced cardiomyopathy
Evaluation of idiopathic VT/VF
Evaluation of sudden cardiac arrest survivors
Evaluation of SCD victims
Evaluation of relatives of sudden arrhythmic death syndrome decedents
Diagnostic procedures
Medical management
More topics in this section
Withdrawal of offending agents
Management of cardiac arrest
Management of sustained VT
Management of electrical storm
Management of idiopathic VT/VF
Management of premature ventricular complexes
Management of PVC-induced cardiomyopathy
Management of HF
Beta-blockers
Antiarrhythmic agents
Intravenous amiodarone
Intravenous procainamide
Intravenous magnesium
Intravenous sotalol
Intravenous CCBs
End-of-life care
Nonpharmacologic interventions
Therapeutic procedures
More topics in this section
ICD (technical considerations)
ICD (optimization of device programming)
Wearable cardioverter-defibrillator
Catheter ablation (acute management)
Catheter ablation (secondary prevention)
Catheter ablation (concomitant treatment)
Specific circumstances
More topics in this section
Elderly patients
Pregnant patients
Patients with obesity
Heart transplant recipients
Patients with outflow tract VA
Patients with papillary muscle VA
Patients with interfascicular reentrant VT
Patients with medication-induced arrhythmia
Patients with ACS
Patients with coronary artery spasm
Patients with coronary artery disease (evaluation)
Patients with coronary artery disease (management)
Patients with coronary artery disease (primary prevention of SCD)
Patients with coronary artery disease (secondary prevention of SCD)
Patients with coronary artery disease (management of recurrent VA)
Patients with coronary anomalies
Patients with dilated cardiomyopathy (evaluation)
Patients with dilated cardiomyopathy (primary prevention of SCD)
Patients with dilated cardiomyopathy (secondary prevention of SCD)
Patients with nonischemic cardiomyopathy (evaluation)
Patients with nonischemic cardiomyopathy (primary prevention of SCD)
Patients with nonischemic cardiomyopathy (secondary prevention of SCD)
Patients with nonischemic cardiomyopathy (management of recurrent VA)
Patients with arrhythmogenic RV cardiomyopathy (evaluation)
Patients with arrhythmogenic RV cardiomyopathy (primary prevention of SCD)
Patients with arrhythmogenic RV cardiomyopathy (secondary prevention of SCD)
Patients with HCM (evaluation)
Patients with HCM (primary prevention of SCD)
Patients with HCM (secondary prevention of SCD)
Patients with LV non-compaction cardiomyopathy
Patients with neuromuscular disorders (evaluation)
Patients with neuromuscular disorders (management)
Patients with myocarditis
Patients with cardiac amyloidosis
Patients with cardiac sarcoidosis (primary prevention of SCD)
Patients with cardiac sarcoidosis (secondary prevention of SCD)
Patients with Chagas cardiomyopathy
Patients with valvular heart disease
Patients with congenital heart disease (evaluation)
Patients with congenital heart disease (management)
Patients with long QT syndrome (evaluation)
Patients with long QT syndrome (management)
Patients with Andersen-Tawil syndrome (evaluation)
Patients with Andersen-Tawil syndrome (management)
Patients with short QT syndrome (evaluation)
Patients with short QT syndrome (management)
Patients with Brugada syndrome (evaluation)
Patients with Brugada syndrome (management)
Patients with early repolarization pattern (evaluation)
Patients with early repolarization pattern (management)
Patients with catecholaminergic polymorphic VT (evaluation)
Patients with catecholaminergic polymorphic VT (management)